Gene polymorphisms MTHFR C677T and MTR A2756G as predictive factors in adjuvant chemotherapy for stage III colorectal cancer

Anticancer Research

Volumn 31, Issue 9, 2011, Pages 3057-3062

  Taflin, Helena ^a   Wettergren, Yvonne ^a   Odin, Elisabeth ^a   Carlsson, Göran ^a   Derwinger, Kristoffer ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adjuvant chemotherapy; Colorectal cancer; MTHFR C677T; MTR A2756G; Survival; Toxicity

Indexed keywords

FLUOROURACIL; FOLINIC ACID; METHIONINE SYNTHASE REDUCTASE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); OXALIPLATIN; 5 METHYLTETRAHYDROFOLATE HOMOCYSTEINE METHYLTRANSFERASE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; COLORECTAL CANCER; DIARRHEA; DNA POLYMORPHISM; DRUG INTOXICATION; DRUG TOLERABILITY; FATIGUE; FEMALE; GENOTYPE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MOLECULAR INTERACTION; NAUSEA; PARESTHESIA; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; COLORECTAL TUMOR; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED;

5-METHYLTETRAHYDROFOLATE-HOMOCYSTEINE S-METHYLTRANSFERASE; ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 80051615753     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Socialstyrelsen, Cancer incidence in Sweden 1999. 2001. 2001, Swedish National Board of Health, Stockholm.
2. Macdonald JS: Clinical overview: adjuvant therapy of gastrointestinal cancer. Cancer Chemother Pharmacol 54(Suppl 1): S4-11, 2004.
3. Goodwin RA and Asmis TR: Overview of systemic therapy for colorectal cancer. Clin Colon Rectal Surg 22(4): 251-256, 2009.
4. Danenberg PV, Malli H and Swenson S: Thymidylate synthase inhibitors. Semin Oncol 26(6): 621-631, 1999.
5. Spears CP, Hayes AA, Shahinian AH, Danenberg PV, Frosing R and Gustavsson BG: Deoxyuridylate effects on thymidylate synthase-5-fluorodeoxyuridylate- folate ternary complex formation. Biochem Pharmacol 38(18): 2985-2993, 1989. (Pubitemid 19222943)
6. Spears CP, Gustavsson BG, Mitchell MS, Spicer D, Berne M, Bernstein L and Danenberg PV: Thymidylate synthetase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil. Cancer Res 44(9): 4144-4150, 1984. (Pubitemid 14041649)
7. Huang ZH, Hua D and Li LH: The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population. Cancer Chemother Pharmacol 63(5): 911-918, 2009.
8. Ren DN, Kim IY, Koh SB, Chang SJ, Eom M, Yi SY, Seong SH, Kim MD, Bronner MP and Cho MY: Comparative analysis of thymidylate synthase at the protein, mRNA, and DNA levels as prognostic markers in colorectal adenocarcinoma. J Surg Oncol 100(7): 546-552, 2009.
9. Osian G, Procopciuc L, Vlad L, Iancu C, Mocan T and Mocan L: C677T and A1298C mutations in the MTHFR gene and survival in colorectal cancer. J Gastrointestin Liver Dis 18(4): 455-460, 2009.
10. Fernandez-Peralta AM, Daimiel L, Nejda N, Iglesias D, Medina Arana V and Gonzalez-Aguilera JJ: Association of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epigenetic characteristic of tumors, and response to chemotherapy. Int J Colorectal Dis 25(2): 141-151, 2010.
11. Glimelius B: Biochemical modulation of 5-fluorouracil: a randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Ann Oncol 4(3): 235-240, 1993.
12. Vincenzi B, Schiavon G, Pantano F, Santini D and Tonini G: Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer. Nat Clin Pract Oncol 5(8): 455-465, 2008.
13. Derwinger K, Carlsson G and Gustavsson B: A study of lymph node ratio as a prognostic marker in colon cancer. Eur J Surg Oncol 34(7): 771-775, 2008.
14. Etienne-Grimaldi MC, Francoual M, Formento JL and Milano G: Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer. Pharmacogenomics 8(11): 1561-1566, 2007. (Pubitemid 350286400)
15. Derwinger K, Wettergren Y, Odin E, Carlsson G and Gustavsson B: A study of the MTHFR gene polymorphism C677T in colorectal cancer. Clin Colorectal Cancer 8(1): 43-48, 2009.
16. Odin E, Wettergren Y, Carlsson G, Danenberg PV, Termini A, Willen R and Gustavsson B: Expression and clinical significance of methylenetetrahydrofolate reductase in patients with colorectal cancer. Clin Colorectal Cancer 5(5): 344-349, 2006. (Pubitemid 43280064)
17. Gusella M, Frigo AC, Bolzonella C, Marinelli R, Barile C, Bononi A, Crepaldi G, Menon D, Stievano L, Toso S, Pasini F, Ferrazzi E, and Padrini R: Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. Br J Cancer 100(10): 1549-1557, 2009.
18. Marcuello E, Altes A, Menoyo A, Rio ED and Baiget M: Methylenetetrahydrofolate reductase gene polymorphisms: Genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? Cancer Chemother Pharmacol 57(6): 835-840, 2006.
19. Tejpar S, Bertagnolli M, Bosman F, Lenz HJ, Garraway L, Waldman F, Warren R, Bild A, Collins-Brennan D, Hahn H, Harkin DP, Kennedy R, Ilyas M, Morreau H, Proutski V, Swanton C, Tomlinson I, Delorenzi M, Fiocca R, Van Cutsem E and Roth A: Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist 15(4): 390-404, 2010.
20. Jass JR: Colorectal cancer: a multipathway disease. Crit Rev Oncog 12(3-4): 273-287, 2006.
21. Jass JR: Molecular heterogeneity of colorectal cancer: Implications for cancer control. Surg Oncol 16(Suppl 1): S7-9, 2007.
22. Yu K, Zhang J, Zhang J, Dou C, Gu S, Xie Y, Mao Y, and Ji C: Methionine synthase A2756G polymorphism and cancer risk: a meta-analysis. Eur J Hum Genet 18: 370-378, 2009.
23. Steck SE, Keku T, Butler LM, Galanko J, Massa B, Millikan RC and Sandler RS: Polymorphisms in methionine synthase, methionine synthase reductase and serine hydroxymethyl-transferase, folate and alcohol intake, and colon cancer risk. J Nutrigenet Nutrigenomics 1(4): 196-204, 2008. (Pubitemid 351873358)
24. Derwinger K, Carlsson G and Gustavsson B: Stage migration in colorectal cancer related to improved lymph node assessment. Eur J Surg Oncol 33(7): 849-853, 2007. (Pubitemid 47279054)